The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C

1999 ◽  
Vol 116 (1) ◽  
pp. 127-134 ◽  
Author(s):  
Lili Kazemi-Shirazi ◽  
Christian Datz ◽  
Theresia Maier-Dobersberger ◽  
Klaus Kaserer ◽  
Franz Hackl ◽  
...  
Author(s):  
Francesco Negro ◽  
Kaveh Samii ◽  
Laura Rubbia-Brandt ◽  
Rafael Quadri ◽  
Pierre-Jean Male ◽  
...  

2009 ◽  
Vol 23 (12) ◽  
pp. 822-828 ◽  
Author(s):  
Leslie Price ◽  
Kris V Kowdley

Increased hepatic iron content may be observed in patients with chronic hepatitis C infection, and may contribute to disease severity. The presence of hemochromatosis gene mutations is associated with increased hepatic iron accumulation and may lead to accelerated disease progression. Hepatic iron depletion has been postulated to decrease the risk of hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. It is possible that iron depletion stabilizes or improves liver histology and slows disease progression in these individuals. The present article reviews the prevalence and risk factors for hepatic iron overload in chronic hepatitis C, with emphasis on the available data regarding the efficacy of iron depletion in the treatment of this common liver disease.


2004 ◽  
Vol 24 (4) ◽  
pp. 285-294 ◽  
Author(s):  
Andreas Geier ◽  
Michael Reugels ◽  
Ralf Weiskirchen ◽  
Hermann E. Wasmuth ◽  
Christoph G. Dietrich ◽  
...  

2012 ◽  
Vol 49 (1) ◽  
pp. 9-13 ◽  
Author(s):  
Silvia Coelho-Borges ◽  
Hugo Cheinquer ◽  
Fernando Herz Wolff ◽  
Nelson Cheinquer ◽  
Luciano Krug ◽  
...  

CONTEXT: Abnormal serum ferritin levels are found in approximately 20%-30% of the patients with chronic hepatitis C and are associated with a lower response rate to interferon therapy. OBJECTIVE: To determine if the presence of HFE gene mutations had any effect on the sustained virological response rate to interferon based therapy in chronic hepatitis C patients with elevated serum ferritin. METHODS: A total of 44 treatment naÏve patients with histologically demonstrated chronic hepatitis C, all infected with hepatitis C virus genotype non-1 (38 genotype 3; 6 genotype 2) and serum ferritin above 500 ng/mL were treated with interferon (3 MU, 3 times a week) and ribavirin (1.000 mg, daily) for 24 weeks. RESULTS: Sustained virological response was defined as negative qualitative HCV-RNA more than 24 weeks after the end of treatment. Serum HCV-RNA was measured by qualitative in house polymerase chain reaction with a limit of detection of 200 IU/mL. HFE gene mutation was detected using restriction-enzyme digestion with RsaI (C282Y mutation analysis) and BclI (H63D mutation analysis) in 16 (37%) patients, all heterozygous (11 H63D, 2 C282Y and 3 both). Sustained virological response was achieved in 0 of 16 patients with HFE gene mutations and 11 (41%) of 27 patients without HFE gene mutations (P = 0.002; exact Fisher test). CONCLUSION: Heterozigozity for H63D and/or C282Y HFE gene mutation predicts absence of sustained virological response to combination treatment with interferon and ribavirin in patients with chronic hepatitis C, non-1 genotype and serum ferritin levels above 500 ng/mL.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1860-1860
Author(s):  
Domenico Girelli ◽  
Michela Pasino ◽  
Julia Goodnough ◽  
Elizabeta Nemeth ◽  
Annalisa Castagna ◽  
...  

Abstract Patients with chronic hepatitis C (CHC) often have increased liver iron deposits, a condition associated with reduced sustained response to antiviral therapy, more rapid progression to cirrhosis, and development of hepatocellular carcinoma. The hepatic hormone hepcidin is a major regulator of iron metabolism that inhibits iron absorption and recycling from erythrophagocytosis. Hepcidin decrease is a possible pathophysiological mechanism of iron overload in CHC, but studies in humans have been hampered so far by the lack of reliable quantitative assays for the 25-amino acid bioactive peptide in serum (s-hepcidin). Using a recently validated immunoassay (Ganz T, Blood 2008, epub Aug 8), we measured s-hepcidin levels in 82 CHC naïve patients and 57 sex-matched healthy controls with rigorous definition of normal iron status. All CHC patients underwent liver biopsy with histological iron score (according to Deugnier YM, Gastroenterology 1992). S-hepcidin was much lower in CHC than in controls (geometric means with 95% CIs: 33.7, 21.5–52.9 versus 90.9, 76.1–108.4 ng/ml, respectively; P<0.001), while both serum ferritin and transferrin saturation were significantly higher in CHC than in controls, as expected. S-hepcidin strongly correlated with serum ferritin in both controls (r=0.741; P<0.001) and CHC patients (r = 0.718; P<0.001). In CHC patients, s-hepcidin also correlated with histological total iron score (r = 0.46; P<0.001), but not with serum interleukin-6 (r = −0.042; P = n.s.). After stratification for serum ferritin quartiles, s-hepcidin levels increased significantly across quartiles in both controls and CHC patients (chi for trend, P<0.001). However, in the latter group s-hepcidin levels were significantly lower than in controls for each corresponding quartile (ANOVA, P<0.001). In the lowest ferritin quartile, s-hepcidin was significantly inversely correlated with viral loading (e.g. serum HCV-RNA IU/ml; r = −0.526; P=0.036), while this association gradually disappeared with increasing ferritin quartiles. These results, together with very recent studies in animal and cellular models (Nishina S, Gastroenterology 2008; Miura K, Hepatology 2008), indicate that though hepcidin regulation by iron stores is maintained in CHC, the suppression of this hormone by HCV is likely an important factor in liver iron accumulation in this condition.


2005 ◽  
Vol 100 ◽  
pp. S130
Author(s):  
Mohammadreza Agah ◽  
Zahra Motahari ◽  
Maryam Zafarghandi ◽  
Hossein Sendi ◽  
Samad Amini ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document